Drug Trial Radar · NCT07661173
A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
154
Planned (sponsor's estimate)
Start
Jun 6, 2026
Primary completion
Mar 6, 2029
Study completion May 6, 2031
Sponsor
- Lead sponsor
- Anhui Provincial Cancer HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Exploring the efficacy and safety of adaptively adjusting treatment regimens based on ctDNA (MRD) status for EGFR mutation-positive NSCLC
Conditions
- Non Small Cell Lung Cancer
Interventions
FirmonertinibDrug
80mg QD
Firmonertinib/pemetrexed/CarboplatinDrug
Drug: Firmonertinib daily and pemetrexed plus carboplatin on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by firmonertinib daily with pemetrexed maintenance every 3 weeks.
Firmonertinib/pemetrexed/Carboplatin/BevacizumabDrug
Drug: Firmonertinib daily and pemetrexed plus carboplatin on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by firmonertinib daily with pemetrexed and bevacizumab maintenance every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: through study completion, an average of 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.